INS and metabolic dysfunction-associated steatohepatitis: PPARα is a validated target in the treatment of liver steatosis, and despite several single or dual PPARα/δ agonists have been proven effective in ameliorating insulin sensitivity and liver steatosis in preclinical models of NASH, clinical trials have shown that these agents hold limited efficacy in clinical settings, strongly supporting the notion that treatment of NASH requires a multitarget approach (Perakakis et al., 2021; Schattenberg et al., 2021; van den Hoek et al., 2021).